Abstract
The last decades of research in schizophrenia witnessed a shift of etiological speculation from neurotransmitters to inflammation. However, identifying definite inflammatory effectors of schizophrenia remains elusive due to confounding factors such as medication and metabolic status. To tackle this issue, we carried out omnigenic-based Mendelian randomization (MR) analysis to explore the inflammatory responses of schizophrenia and the brain morphological consequences caused by these SCZ-triggering inflammation responses. Our results identified seven SCZ-triggering inflammation markers, with P values surviving the Bonferroni multiple comparisons (B_NGF, P = 1.45 × 10−8; GROA (CXCL1) P = 1.15 × 10−4; IL8, P = 3.64 × 10−7; MCSF, P = 9.30 × 10−4; MCP3 (CCL7), P = 1.3 × 10−6; TNF_β, P = 3.63 × 10−4; CRP, P = 1.71 × 10−32). Further, three of them, GROA (CXCL1), IL8 and CRP, could lead to significant linear change rate of brain morphologies, especially white matter in both cerebral and cerebellum. Our study is the first to use an omnigenic conceptual framework to capture the immune pathology of schizophrenia. Although future studies adopting a different methodology are needed to validate our results, our study provides another piece of evidence that extensive and low-grade neuroinflammation exists in schizophrenia and that some of these inflammation markers could be potential targets for the precise diagnosis and treatment of schizophrenia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
fundings: the National Natural Science Foundation of China (grant number 81920108018), the Key R & D Program of Zhejiang (grant number 2022C03096), Project for Hangzhou Medical Disciplines of Excellence.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* xuntao26{at}hotmail.com
Data Availability
Summary statistics of SCZ GWAS: https://doi.org/10.6084/m9.figshare.19426775; Summary statistics of GWAS of cytokine level in the peripheral blood: https://research-information.bris.ac.uk/en/datasets/cytokines-gwas-results; Summary statistics of GWAS of longitudinal change of brain morphology: http://enigma.ini.usc.edu/research/download-enigma-gwas-results
